These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9549664)

  • 1. Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects.
    Patat A; Troy S; Burke J; Trocherie S; Danjou P; Le Coz F; Allain H; Gandon JM
    J Clin Pharmacol; 1998 Mar; 38(3):256-67. PubMed ID: 9549664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative bioavailability of two formulations of venlafaxine extended-release 75-mg capsules in healthy brazilian male volunteers: A single-dose, randomized-sequence, open-label, two-period crossover study in the fasting and fed states.
    Homero de Souza Filho J; Bonifácio FN; Bedor DC; Ramos VL; de Sousa CE; Sardón LL; Gonçalves TM; Moreira RC; Leal LB; de Santana DP
    Clin Ther; 2010 Nov; 32(12):2088-96. PubMed ID: 21118744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study.
    Chenu F; Batten LA; Zernig G; Ladstaetter E; Hébert C; Blier P
    J Clin Psychiatry; 2009 Jul; 70(7):958-66. PubMed ID: 19653973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
    J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine.
    Troy SM; Parker VP; Hicks DR; Pollack GM; Chiang ST
    J Clin Pharmacol; 1997 Oct; 37(10):954-61. PubMed ID: 9505987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.
    Jann MW; Spratlin V; Momary K; Zhang H; Turner D; Penzak SR; Wright A; VanDenBerg C
    Eur J Clin Pharmacol; 2012 May; 68(5):715-21. PubMed ID: 22173281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venlafaxine extended-release for depression following spinal cord injury: a randomized clinical trial.
    Fann JR; Bombardier CH; Richards JS; Wilson CS; Heinemann AW; Warren AM; Brooks L; McCullumsmith CB; Temkin NR; Warms C; Tate DG;
    JAMA Psychiatry; 2015 Mar; 72(3):247-58. PubMed ID: 25607727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
    Bielski RJ; Ventura D; Chang CC
    J Clin Psychiatry; 2004 Sep; 65(9):1190-6. PubMed ID: 15367045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release.
    Rickels K; Etemad B; Khalid-Khan S; Lohoff FW; Rynn MA; Gallop RJ
    Arch Gen Psychiatry; 2010 Dec; 67(12):1274-81. PubMed ID: 21135327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group.
    Cunningham LA
    Ann Clin Psychiatry; 1997 Sep; 9(3):157-64. PubMed ID: 9339881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.
    Feighner JP; Entsuah AR; McPherson MK
    J Affect Disord; 1998 Jan; 47(1-3):55-62. PubMed ID: 9476744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR.
    Montgomery SA; Sheehan DV; Meoni P; Haudiquet V; Hackett D
    J Psychiatr Res; 2002; 36(4):209-17. PubMed ID: 12191625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder.
    Lydiard RB; Pitrosky B; Hackett D; White C
    J Clin Psychiatry; 2004 Jun; 65(6):838-44. PubMed ID: 15291662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
    Thase ME
    J Clin Psychiatry; 1997 Sep; 58(9):393-8. PubMed ID: 9378690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G; Gislum M; Filippov G; Montgomery S
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of depression with different formulations of venlafaxine: a comparative analysis.
    Olver JS; Burrows GD; Norman TR
    Hum Psychopharmacol; 2004 Jan; 19(1):9-16. PubMed ID: 14716706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.
    Levin FR; Mariani J; Brooks DJ; Pavlicova M; Nunes EV; Agosti V; Bisaga A; Sullivan MA; Carpenter KM
    Addiction; 2013 Jun; 108(6):1084-94. PubMed ID: 23297841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression.
    Entsuah R; Chitra R
    Psychopharmacol Bull; 1997; 33(4):671-6. PubMed ID: 9493478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.